Edwards Lifesciences Corporation (EW) Stock Score, Valuation & Financial Research
Edwards Lifesciences Corporation is in the Healthcare sector and Medical - Devices industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 44/100.
Quick answer for EW
Edwards Lifesciences Corporation currently has a Wall Street Score of 44/100. The stored market price is $84.37. Its financial score is 47/100. Its valuation score is 4/100. These figures are a research snapshot, not a buy or sell recommendation.
What Edwards Lifesciences Corporation does
Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascendin
EW financial snapshot
- Wall Street Score:
- 44/100
- Current price:
- $84.37
- Market capitalization:
- $48.58B
- Revenue:
- $6.51B
- Net income:
- $1.00B
- Free cash flow:
- $1.33B
- Cash:
- $2.91B
- Total debt:
- $704.4M
- EPS:
- 1.74
- P/E ratio:
- 48.5x
- Financial score:
- 47/100
- Valuation score:
- 4/100
- Revenue score:
- 25/100
What stands out
- Reported year-over-year revenue growth is +0.1%.
- Free cash flow is $1.33B, showing positive cash generation.
- The balance sheet shows $2.91B of cash versus $704.4M of total debt, leaving more cash than debt.
What the numbers mean
Its current valuation score is 4/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 47/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-07.
How to research EW
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.